Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer
DOI: 10.1055/s-0043-1762939
Letter to the Editor

Lenvatinib Can Overcome Immune Resistance in Head and Neck Cancer and Achieve Durable Remission

Oshin Suri
1   Department of Medical Oncology, Artemis Hospital, Gurugram, India
,
Vineet Govinda Gupta
1   Department of Medical Oncology, Artemis Hospital, Gurugram, India
› Author Affiliations
› Further Information
   Permissions and Reprints
Zoom Image
Vineet Govinda Gupta

Squamous cell carcinoma head and neck is the sixth most common cancer worldwide and.[1] Multimodality therapies have been advocated for locoregional relapse or metastatic disease.[2] Combination therapy with lenvatinib has been considered to overcome resistance and improve the efficacy.[3] In a recent study of lenvatinib and pembrolizumab conducted in heavily pretreated recurrent and metastatic head and neck cancer, the median overall survival OS was 6.2 months, and the median progression-free survival (PFS) was 4.6 months.[4]

This combination is currently undergoing study in LEAP-010.[5] Herein, we report a case of heavily pretreated metastatic head and neck cancer in a patient who was treated with a combination of lenvatinib with pembrolizumab.



Publication History

Article published online:
09 March 2023

© 2023. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Ferlay J, Colombet M, Soerjomataram I. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019; 144 (08) 1941-1953
    CrossrefPubMedGoogle Scholar
  • 2 Karabajakian A, Toussaint P, Neidhardt EM, Paulus V, Saintigny P, Fayette J. Chemotherapy for recurrent/metastatic head and neck cancers. Anticancer Drugs 2017; 28 (04) 357-361
    CrossrefPubMedGoogle Scholar
  • 3 Morrissey KM, Yuraszeck TM, Li CC, Zhang Y, Kasichayanula S. Immunotherapy and novel combinations in oncology: current landscape, challenges and opportunities. Clin Transl Sci 2016; 9 (02) 89-104
    CrossrefPubMedGoogle Scholar
  • 4 Chen T-H, Chang PM, Yang MH. Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pretreated recurrent and metastatic head and neck cancer. J Chin Med Assoc 2021; 84 (04) 361-367
    CrossrefPubMedGoogle Scholar
  • 5 Merck Sharp & Dohme Corp. . 2022. A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010) (LEAP-10) (Clinical Trial Registration No. NCT04199104). clinicaltrials.gov. Accessed January 25, 2023. https://clinicaltrials.gov/ct2/show/NCT04199104